Hormone-Resistant Breast Cancer—Evolving Management and New Targets Cancer Network The good news is that there are a set of drugs that target the PI3 kinase pathway—mTOR inhibitors, AKT inhibitors, and inhibitors of the receptor tyrosine kinases themselves, all of which are in various phases of ongoing clinical trials. |
